AADI VS PBYI Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment

Performance

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

PBYI
100/100

PBYI returned 4.80% in the last 12 months. Based on SPY's performance of -21.18%, its performance is above average giving it a score of 100 of 100.

Technicals

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

PBYI
36/100

PBYI receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

PBYI
10/100

PBYI has missed earnings 6 times in the last 20 quarters.

Profit

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

PBYI
34/100

Out of the last 20 quarters, PBYI has had 6 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

PBYI
48/100

PBYI has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Analyst Price Targets

AADI

"Analyst Price Targets" not found for AADI

PBYI
83/100

9 analysts offer 12-month price targets for PBYI. Together, they have an average target of 0, the most optimistic target put PBYI at 0 within 12-months and the most pessimistic has PBYI at 0.

Sentiment

AADI

"Sentiment" not found for AADI

PBYI
65/100

PBYI had a bullish sentiment score of 65.49% across Twitter and StockTwits over the last 12 months. It had an average of 5.77 posts, 2.74 comments, and 4.22 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

PUMA BIOTECHNOLOGY INC Summary

Nasdaq / PBYI
Healthcare
Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.